BTC $62,265.03 -1.00%
ETH $1,773.18 -0.84%
BNB $567.62 -0.08%
XRP $1.06 -0.92%
SOL $74.55 -1.79%
TRX $0.3242 -1.93%
DOGE $0.0714 -0.76%
ADA $0.1562 -1.11%
BCH $232.07 -1.90%
LINK $7.86 -0.52%
HYPE $62.70 -5.90%
AAVE $95.51 +0.36%
SUI $0.7191 -0.70%
XLM $0.1780 -2.54%
ZEC $498.56 -4.07%
BTC $62,265.03 -1.00%
ETH $1,773.18 -0.84%
BNB $567.62 -0.08%
XRP $1.06 -0.92%
SOL $74.55 -1.79%
TRX $0.3242 -1.93%
DOGE $0.0714 -0.76%
ADA $0.1562 -1.11%
BCH $232.07 -1.90%
LINK $7.86 -0.52%
HYPE $62.70 -5.90%
AAVE $95.51 +0.36%
SUI $0.7191 -0.70%
XLM $0.1780 -2.54%
ZEC $498.56 -4.07%

Chainalysis: Gray market peptide suppliers are rapidly shifting to Bitcoin and stablecoins, with a year-on-year surge of 159% in crypto inflows in Q1

2026-06-05 08:24:45
Collection

According to The Block, blockchain analytics company Chainalysis has released a latest report indicating that as the gray market peptide industry scales surpasses an annualized $100 million, leading suppliers are accelerating the adoption of Bitcoin and stablecoins as primary settlement tools.

In Q1 2026, cryptocurrency inflows into the industry reached $32 million, a month-on-month surge of 159%. Due to traditional banks and credit card payment channels generally imposing bans on prescription-grade compounds and unregulated substances, a large number of Chinese chemical manufacturers are turning to cryptocurrency to complete transactions, with high-value orders particularly favoring stablecoins to avoid price volatility risks.

app_icon
ChainCatcher Building the Web3 world with innovations.